A Phase 1/2 interventional study of Placebo and Brincidofovir in Viruria, sponsored by Chimerix. Completed at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-16.
Sponsored by Chimerix (part of Jazz Pharmaceuticals) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus viruria.
This was a randomized, double-blind, multiple-dose placebo-controlled study of oral brincidofovir (BCV) in hematopoietic stem cell transplant and renal transplant recipients with BK virus infection.
Subjects received blinded study medication for a total of 5 doses in 1 of the following regimens:
Chimerix is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.
First submitted before Chimerix became part of Jazz Pharmaceuticals.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For inclusion into the trial, subjects were required to fulfill all of the following criteria:
Were renal or hematopoietic stem cell transplant patients who met the following criteria:
Renal transplant patients who:
Stem cell transplant patients who:
Exclusion Criteria
Any of the following was regarded as a criterion for exclusion from the trial:
Were stem cell transplant patients who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Under Amendments 1 and 2, subjects received 1 of 2 dose regimens of brincidofovir, as follows: * 20 mg BCV once weekly (QW) on Days 0, 7, and 14; or * 10 mg BCV twice weekly (BIW) BIW on Days 0, 3, 7, 10, and 14. Under Amendment 3, subjects received 40 mg BCV QW for a total of 5 doses on Days 0, 7, 14, 21, and 28.
Drug: Brincidofovir
Under Amendments 1 and 2, subjects received placebo twice weekly (BIW) for a total of 5 doses on Days 0, 3, 7, 10, and 14. Under Amendment 3, subjects received placebo once weekly (QW) for a total of 5 doses on Days 0, 7, 14, 21, and 28.
Drug: Placebo
Also known as: BCV, CMX001
Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria
The primary objective of this study was to determine the safety and tolerability of brincidofovir (BCV) in post-transplant patients with BK virus viruria. Safety measures included adverse events, clinical laboratory values, vital signs, and renal and gastrointestinal function.
Time frame: 35 days (Day 0 to Day 35)
Percentage of Patients Who Achieved BK Viruria Resolution
The percentage of subjects who cleared the virus was calculated. Concentrations below the lower limit of quantification were indicated as below the limit of quantitation and were considered "cleared".
Time frame: 28 days
Number of Patients Who Achieved a Clinically Significant Decrease in BK Viruria
A 2-log drop in viruria or viremia or clearance of virus was considered significant. Percentages of subjects with a 2-log drop in viral load were calculated.
Time frame: 28 days
| Milestone | 10 mg BCV BIW RT | 10 mg BCV BIW HCT | 20 mg BCV QW HCT | Placebo BIW HCT | 40 mg BCV QW RT | 40 mg BCV QW HCT | Placebo QW RT | Placebo QW HCT |
|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 2 | 8 | 8 | 4 | 4 |
| Completed | 1 | 0 | 1 | 2 | 8 | 7 | 4 | 3 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Patient request | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Subject not dosed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
The primary objective of this study was to determine the safety and tolerability of brincidofovir (BCV) in post-transplant patients with BK virus viruria. Safety measures included adverse events, clinical laboratory values, vital signs, and renal and gastrointestinal function.
| Participants | 10 mg BCV BIW RT | 10 mg BCV BIW HCT | 20 mg BCV BIW HCT | Placebo BIW HCT | 40 mg BCV QW RT | 40 mg BCV QW HCT | Placebo QW RT | Placebo QW HCT |
|---|---|---|---|---|---|---|---|---|
| Subjects who experienced at least 1 an adverse event | 1 | 1 | 1 | 2 | 8 | 7 | 3 | 4 |
| Subjects who did not experience an adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
The percentage of subjects who cleared the virus was calculated. Concentrations below the lower limit of quantification were indicated as below the limit of quantitation and were considered "cleared".
| Participants | 40 mg BCV QW | Placebo |
|---|---|---|
| HCT recipients — Subjects who cleared viruria | 1 | 0 |
| HCT recipients — Subjects who did not clear viruria | 6 | 4 |
| RT Recipients — Subjects who cleared viruria | 1 | 0 |
| RT Recipients — Subjects who did not clear viruria | 7 | 4 |
A 2-log drop in viruria or viremia or clearance of virus was considered significant. Percentages of subjects with a 2-log drop in viral load were calculated.
| Participants | 40 mg BCV QW | Placebo QW |
|---|---|---|
| HCT recipients — Subjects with 2-log drop from Day 0 | 1 | 1 |
| HCT recipients — Subjects without 2-log drop from Day 0 | 6 | 3 |
| RT Recipients — Subjects with 2-log drop from Day 0 | 0 | 0 |
| RT Recipients — Subjects without 2-log drop from Day 0 | 8 | 4 |
Collected over Day 0 to Day 35. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 mg BCV BIW RT | — | 1/1 (100%) | 1/1 (100%) |
| 10 mg BCV BIW HCT | — | 0/1 (0%) | 1/1 (100%) |
| 20 mg BCV QW HCT | — | 0/1 (0%) | 1/1 (100%) |
| Placebo BIW HCT | — | 0/2 (0%) | 2/2 (100%) |
| 40 mg BCV QW RT | — | 0/8 (0%) | 8/8 (100%) |
| 40 mg BCV QW HCT | — | 2/7 (28.6%) | 7/7 (100%) |
| Placebo QW RT | — | 0/4 (0%) | 3/4 (75%) |
| Placebo QW HCT | — | 1/4 (25%) | 4/4 (100%) |
| Event | 10 mg BCV BIW RT | 10 mg BCV BIW HCT | 20 mg BCV QW HCT | Placebo BIW HCT | 40 mg BCV QW RT | 40 mg BCV QW HCT | Placebo QW RT | Placebo QW HCT |
|---|---|---|---|---|---|---|---|---|
| Pancreas transplant rejectionImmune system disorders | 1/1 | 0/1 | 0/1 | 0/2 | 0/8 | 0/7 | 0/4 | 0/4 |
| Acute graft versus host disease in intestineImmune system disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/8 | 0/7 | 0/4 | 1/4 |
| PyrexiaGeneral disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/8 | 0/7 | 0/4 | 1/4 |
| MethemoglobinemiaBlood and lymphatic system disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/8 | 0/7 | 0/4 | 1/4 |
| HaematuriaRenal and urinary disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/8 | 1/7 | 0/4 | 0/4 |
| OliguriaRenal and urinary disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/8 | 1/7 | 0/4 | 0/4 |
| Acute graft versus host disease skinImmune system disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/8 | 1/7 | 0/4 | 0/4 |
| PneumoniaInfections and infestations | 0/1 | 0/1 | 0/1 | 0/2 | 0/8 | 1/7 | 0/4 | 0/4 |
| Event | 10 mg BCV BIW RT | 10 mg BCV BIW HCT | 20 mg BCV QW HCT | Placebo BIW HCT | 40 mg BCV QW RT | 40 mg BCV QW HCT | Placebo QW RT | Placebo QW HCT |
|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/1 | 1/1 | 0/1 | 0/2 | 3/8 | 2/7 | 0/4 | 2/4 |
| Blood amylase increasedInvestigations | 1/1 | 0/1 | 0/1 | 0/2 | 1/8 | 0/7 | 0/4 | 0/4 |
| Lipase increasedInvestigations | 1/1 | 0/1 | 0/1 | 0/2 | 1/8 | 0/7 | 0/4 | 0/4 |
| OsteopeniaMusculoskeletal and connective tissue disorders | 0/1 | 0/1 | 0/1 | 2/2 | 0/8 | 0/7 | 0/4 | 2/4 |
| EcchymosisSkin and subcutaneous tissue disorders | 0/1 | 0/1 | 1/1 | 0/2 | 0/8 | 0/7 | 0/4 | 0/4 |
| CellulitisInfections and infestations | 0/1 | 0/1 | 1/1 | 0/2 | 0/8 | 0/7 | 0/4 | 0/4 |
| Oedema peripheralGeneral disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/8 | 4/7 | 0/4 | 0/4 |
| NauseaGastrointestinal disorders | 0/1 | 0/1 | 0/1 | 1/2 | 1/8 | 3/7 | 0/4 | 2/4 |
| VomitingGastrointestinal disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/8 | 1/7 | 0/4 | 2/4 |
| FatigueGeneral disorders | 0/1 | 0/1 | 0/1 | 1/2 | 1/8 | 2/7 | 0/4 | 1/4 |
1 HCT subject in the 40 mg BCV QW treatment arm was not dosed with BCV and, therefore, is not included in this analysis.
| Age, Continuous(years) | 10 mg BCV BIW | 20 mg BCV QW | Placebo BIW | 40 mg BCV QW | Placebo QW | Total |
|---|---|---|---|---|---|---|
| Mean | 40 ± 10 | 60 ± 0 | 60 ± 2 | 55.5 ± 15.14 | 51.0 ± 10.46 | 51.5 ± 14.2 |
| Sex: Female, Male(Participants) | 10 mg BCV BIW | 20 mg BCV QW | Placebo BIW | 40 mg BCV QW | Placebo QW | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 1 | 3 | 4 | 8 |
| Male | 2 | 1 | 1 | 12 | 4 | 20 |
| Type of transplant received(Participants) | 10 mg BCV BIW | 20 mg BCV QW | Placebo BIW | 40 mg BCV QW | Placebo QW | Total |
|---|---|---|---|---|---|---|
| Hematopoietic stem cell transplant recipients | 1 | 1 | 2 | 7 | 4 | 15 |
| Renal transplant recipients | 1 | 0 | 0 | 8 | 4 | 13 |
Ran from Nov 2009 to primary completion in Oct 2010, 11 months.
Results were first posted in Jul 2021, 10 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brincidofovir